Disclosure: Published by Affinity AI, a pharmacy-connectivity business. Examples below are fictional purchasing illustrations, not actual pharmacy quotes or treatment recommendations.
The short answer
Compare compounding pharmacies in two stages. First, establish that each option is clinically appropriate, legally eligible for the intended order, licensed for the destination, and acceptable to your quality team. Then compare the exact formulation and package using total delivered cost, usable quantity, turnaround, and support performance. The lowest vial price is not necessarily the lowest cost of a successfully completed order.
This approach matters whether you operate a single medspa or a telehealth brand shipping to multiple states. Your comparison needs to answer a specific question: Which qualified supplier can fulfill this prescribed product, for this patient or permitted office-use order, to this destination, at a clearly stated total cost?
Start with eligibility, not a price ranking
A quote is not useful if the supplier cannot fulfill your order lawfully or if the product does not fit the prescription. Treat those issues as pass/fail requirements. Do not award a low price enough points to compensate for a failed eligibility check.
Before requesting competing quotes, have the appropriate clinical and pharmacy professionals confirm the intended preparation, why compounding is appropriate, and the ordering model. FDA explains that compounded medications are not FDA-approved and are not the same as approved generic drugs. FDA: Compounding Questions and Answers
Your initial gates should include:
- Exact legal identity and location of the dispensing or compounding facility.
- Patient-specific prescription versus eligible office-use purchasing.
- Applicable facility and destination-state permissions.
- Product-specific compounding eligibility.
- Clinical acceptance of the formulation, packaging, and instructions.
- Completion of your documented supplier-quality review.
Only qualified options move into the economic comparison. If none qualify, the answer is not to relax the gates; it is to revisit the sourcing plan with the responsible professionals.
Build one normalized formulary row per product
"Same medication" is not a sufficient comparison field. One listing may describe concentration, another total content, and another a package containing several containers. Combination preparations introduce additional differences.
Use this template for every quote:
Field | What to record | Why it matters |
|---|---|---|
| Facility | Legal name, address, identifier | Identifies the actual source |
| Active ingredients | Full ingredient names and forms | Prevents mismatching different preparations |
| Strength or concentration | Units per tablet, capsule, mL, or gram | Establishes the labeled product strength |
| Fill quantity | Actual volume, mass, or unit count | Separates container size from contents |
| Package | Containers per order; single-dose or multidose presentation | Changes handling and usable quantity |
| Formulation | Dosage form, route, vehicle, relevant excipients | Requires clinical review, not automatic substitution |
| Ordering model | Named-patient prescription or permitted office-use order | Defines the purchasing pathway |
| Storage and dating | Labeled storage; remaining dating; after-opening instructions | Affects suitability and waste |
| Commercial terms | Product charge, all fees, freight, discounts | Establishes landed cost |
| Availability | Status, confirmation time, expected release date | Distinguishes a catalog entry from supply |
| Destination | Patient or clinic state and delivery address type | Defines the actual shipping scenario |
For a liquid, the basic accounting identity is:
Total labeled ingredient content = concentration × actual fill volume × container count.
For capsules or tablets:
Total labeled ingredient content = labeled strength per unit × unit count.
These are purchasing calculations, not dosing instructions. Record each ingredient separately for combination products. Do not add the milligrams of different ingredients into one denominator or compare different active ingredients by "cost per milligram."
Even a numerically identical total content does not establish clinical interchangeability. Differences in concentration, excipients, route, container, or instructions require appropriate prescriber and pharmacist review.
A worked comparison: why vial price can mislead
Consider three fictional quotes for a hypothetical preparation. The example deliberately avoids naming a drug: it demonstrates arithmetic, not an available or appropriate prescription.
Quote detail | Supplier A | Supplier B | Supplier C |
|---|---|---|---|
| Labeled concentration | 5 mg/mL | 5 mg/mL | 10 mg/mL |
| Actual fill volume | 2 mL | 2 mL | 2 mL |
| Total labeled content | 10 mg | 10 mg | 20 mg |
| Product price | $120 | $128 | $180 |
| Shipping | $25 | $10 | $25 |
| Service charge | $5 | $0 | $5 |
| Landed total | $150 | $138 | $210 |
| Landed cost per labeled mg | $15.00 | $13.80 | $10.50 |
Supplier B has the higher product price but the lower delivered price than A. Supplier C has the lowest nominal cost per milligram, but a different concentration and twice the total content. It is not an automatic substitute or the default winner.
If a larger package cannot be appropriately used within its applicable dating and handling limits, its theoretical unit-cost advantage may disappear. A lower-cost purchase that forces a concentration change may also add clinical review, patient education, and operational work.
FDA has documented dosing errors associated with varying compounded semaglutide concentrations and confusion between milligrams, milliliters, and syringe units. That is a concrete reason to keep procurement arithmetic separate from prescribing and administration instructions. FDA: Compounded Semaglutide Dosing Errors
Calculate landed cost before discussing savings
Use a consistent formula:
Landed order cost = medication charge + service/platform charges + processing charges + shipping + temperature-controlled packaging + required supplies + applicable taxes − earned discounts.
Not every vendor charges every item. Record a confirmed zero, an included charge, or an unknown rather than assuming an omitted line item is free.
Ask whether fees are assessed per prescription, shipment, pharmacy, package, or monthly account. Those denominators matter. Three prescriptions in one portal can still produce three pharmacy shipments and three freight charges.
For subscription or integration charges, show a separate allocation:
Allocated platform cost per fulfilled order = relevant period's platform charges ÷ fulfilled orders in that period.
Keep prepaid account credits separate from incremental fees. A credit applied to future purchases creates a cash-flow commitment; it should not be counted again as an additional medication expense when redeemed. Review its permitted uses and contractual conditions rather than treating the credit as free money.
When reporting savings, publish the baseline:
Savings percentage = (matched baseline landed cost − matched alternative landed cost) ÷ matched baseline landed cost × 100.
"Matched" means the comparison uses clinically accepted products, equivalent quantities, the same destination and shipping assumptions, and the same date or valid quote period. A discount on one inexpensive SKU does not establish a discount across the entire formulary.
Separate shelf life from usable quantity
Ask the pharmacy to distinguish unopened dating from after-opening or after-puncture instructions and explain the applicable storage conditions. Do not assume a longer printed date permits longer use after opening.
For procurement, record the minimum remaining dating promised at delivery and the documentation supporting it. A beyond-use date is not simply a manufacturer's expiration date copied onto a compounded preparation; USP publishes separate compounding standards and BUD resources. USP: Compounding Standards and Beyond-Use Dates
The buyer's planning metric is:
Cost per usable unit = landed cost ÷ quantity expected to be appropriately used before applicable discard limits.
Use quantities supplied by the clinical or pharmacy team, not a procurement-generated treatment schedule. In a patient-specific order, unused medication is not general stock to reassign to another patient.
Product-specific safety recommendations also matter. FDA currently recommends discarding multidose sterile GLP-1 vials within 28 days after first use even if a compounder's instructions allow longer. Do not apply that statement as a universal dating rule for every compounded product. FDA: Unapproved GLP-1 Safety Concerns
Compare time to delivery, not shipping speed alone
"Overnight shipping" says little about when an order leaves the pharmacy. Break fulfillment into measurable stages:
- Complete order received.
- Prescription and account review completed.
- Preparation available and released.
- Carrier accepts shipment.
- Recipient receives shipment.
Ask the supplier when its turnaround clock starts and what pauses it. Does the estimate exclude clarification requests, weekends, holidays, payment holds, or laboratory release? Is it a recent observed range or an aspirational promise?
Compare the median and a slower-tail measure, such as the 90th percentile, for similar orders if the vendor can provide them. Ask for the measurement period and sample size. A small pilot can reveal workflow defects, but it cannot establish a reliable long-term delivery rate.
For temperature-sensitive shipments, request the qualified shipping configuration, seasonal handling policy, delivery-exception process, and replacement rules. FDA specifically warns against using injectable GLP-1 medication that arrives warm or with inadequate refrigeration. A visible tracking event alone cannot establish acceptable product condition. FDA: Shipping and Storage Concerns
Treat state coverage as a product-level eligibility matrix
A national map is a starting point, not an order approval. The relevant combination is facility + product + ordering model + destination + current authorization.
California illustrates why this matters: its Board of Pharmacy provides separate licensing pathways for pharmacies, sterile compounding pharmacies, and outsourcing facilities, including nonresident facilities. FDA outsourcing registration is not a substitute for the applicable state permissions. California: Facility License Types, California: Outsourcing Facility Licensing
Ask each supplier to complete a matrix for your actual states and top formulations. Record the source, verification date, and owner of each eligibility decision. A commercial promise to "ship nationwide" should not override a restriction in a license record or a product-specific limitation.
Likewise, distinguish availability states:
- Listed in the catalog.
- Accepting prescriptions or orders.
- Scheduled for preparation.
- Released and available for fulfillment.
- Allocated to your accepted order.
Ask how fresh each status is and what event updates it. Do not design routing around "in stock" unless the pharmacy explains exactly what that field means.
Include quality evidence without turning it into a badge contest
Request evidence appropriate to the preparation: relevant licenses, inspection history, release-testing approach, potency or assay data, applicable sterility and endotoxin testing, dating support, shipping validation, and recall procedures. Confirm whether a certificate of analysis describes an ingredient or the finished preparation and whether it is traceable to the relevant lot.
These are due-diligence requests, not a claim that an identical testing document is required for every formulation or batch under every framework.
Review inspection observations in context. An FDA Form 483 records investigators' observations and is not itself a final agency determination. Examine the underlying issues, the response, later findings, and present status. FDA: Form 483 FAQ
A low advertised price cannot resolve an unanswered quality question. Put the supplier on hold until the responsible reviewer has enough evidence to decide.
Measure the cost of avoidable operational work
Once suppliers pass safety and eligibility gates, compare the work surrounding successful orders. Useful measurements include clarification tickets, duplicate-entry time, tracking requests, shipment failures, invoice corrections, and unresolved credit requests.
For example, ten extra support minutes at an assumed loaded labor cost of $30 per hour adds $5 per affected order. That is an illustrative calculation, not an industry benchmark.
Use a separate operating-cost view:
Operational cost per fulfilled order = landed order cost + allocated platform costs + measured administrative labor + unreimbursed operational exception costs.
Avoid double-counting replacements already included in an exception line. Keep clinical safety incidents separate from purchasing optimization; patient harm is not a tradeoff to price into a cheaper supplier choice.
A practical selection checklist
- Match facility, formulation, concentration, package, and order type.
- Complete clinical, legal, licensing, and quality eligibility checks.
- Obtain an itemized quote with a validity date.
- Calculate landed cost and applicable usable quantity.
- Verify shipping conditions and realistic turnaround.
- Confirm availability for the exact product and destination.
- Document support ownership, replacement rules, and cancellation terms.
- Pilot the workflow with appropriate oversight before expanding volume.
- Reconcile actual invoices and delivery results against quoted terms.
Where Affinity AI fits
Affinity AI's public platform describes compounder catalogs, prescription routing, APIs, and fulfillment visibility for practices and platforms. Those capabilities make it relevant to teams evaluating how to coordinate multiple pharmacy relationships. They do not establish that every pharmacy, preparation, destination, or quoted price is currently supported. Affinity: Platform Overview
For a useful evaluation, bring a de-identified list of your top formulations, destination states, current landed costs, and recurring fulfillment problems. Ask Affinity to demonstrate the available workflow against those exact requirements and identify what still needs pharmacy confirmation.
The goal is a documented sourcing decision.
Frequently asked questions
Is cost per milligram the best comparison?
It is an accounting aid only after the products have been appropriately matched. It does not establish therapeutic equivalence, safe substitution, or the amount a patient should use.
Does a larger vial always save money?
No. Package size, applicable discard limits, handling, and the clinically appropriate prescription determine usable quantity. More labeled content is not necessarily more useful content.
Does one checkout mean one shipment?
Not necessarily. Confirm whether products ship separately by pharmacy and how freight and service charges are allocated.
Should a clinic choose the pharmacy with the broadest formulary?
Only if that breadth translates into suitable, eligible products for the clinic's actual needs. A narrower supplier with a dependable match can be more useful than a large catalog with uncertain availability.
What should be rechecked over time?
Recheck quotes when they expire, eligibility when the facility, formulation, destination, or applicable rules change, and performance against actual orders. Review regulatory and quality updates under a documented ongoing process.
Sources and editorial note
Sources are linked next to the claims they support. Regulatory facts were checked against FDA, USP, and California Board of Pharmacy resources on September 16, 2026. Affinity positioning reflects its public website, not an independent product audit. Calculations, comparison templates, and purchasing recommendations are original editorial analysis.
Educational disclaimer: This guide is not medical, pharmacy, legal, or accounting advice. Licensed clinicians and pharmacists must determine clinical appropriateness, prescribing, dispensing, and handling; qualified counsel should review the applicable purchasing and distribution requirements. Availability, prices, laws, and regulatory policies can change.